Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
45/100
Subjects were poor, with low acculturation levels despite long years of U.S. residence.
Why it matters
This community outreach sample of Hispanics found that subjects were poor with low acculturation despite long US residence, which the authors say could point to cultural and genetic risk factors for dementia. It offers no treatment, cure, or prevention.
-
45/100
Language in patients with Alzheimer's disease has been extensively studied, with the exception of non-literal language comprehension.
Why it matters
In 39 patients with probable early Alzheimer's disease, decline in understanding metaphors and idioms was not an early symptom and could occur separately from other language problems. No treatment, cure, or prevention is reported.
-
Oxidative stress and energy depletion are characteristic biochemical hallmarks of Alzheimer's disease (AD), thus antioxidants with positive effects on glucose metabolism such as thioctic (alpha-lipoic) acid should exert positive effects in these patients.
Why it matters
In this open study, nine patients with Alzheimer's disease and related dementias taking standard acetylcholinesterase inhibitors received 600mg alpha-lipoic acid daily for an average of about 337 days, and cognitive scores stayed constant. Because the study was open and involved only nine patients, it cannot establish whether alpha-lipoic acid slows or prevents dementia.
-
This study provides partial validation of specific clinical criteria for apathy in Alzheimer's disease.
-
We studied the prevalence of dementing disorders in a rural town of Japan (Amino-cho), using a door-to-door two-phase design.
Why it matters
In a door-to-door, two-phase survey of people aged 65 and over in Amino-cho, a rural Japanese town, 142 people were diagnosed with dementia, a prevalence of 3.8 per 100: 2.1 for Alzheimer's disease, 1.0 for vascular dementia and 0.7 for other types, including four men with dementia with Lewy bodies. Alzheimer's was more common in women, while vascular dementia was equally common in both sexes, and the authors say the finding that Alzheimer's outnumbers vascular dementia matches "many previous studies in Western countries and some recent surveys in Japan." It counts cases in one town; it does not identify causes, test treatments or give a national rate.
-
A great number of epidemiological studies have demonstrated that the frequency of the epsilon4 allele of the apolipoprotein E gene (APOE) is markedly higher in sporadic and in familial late onset Alzheimer disease (AD).
Why it matters
In frontal cortex tissue from Alzheimer's disease patients, lipid oxidation was significantly elevated in those homozygous for the APOE ε4 allele compared with APOE ε3/ε3 cases and controls, and the antioxidants EGb 761, DHEA, and human recombinant apoE3 protected tissue against hydrogen peroxide/iron-induced damage. This is tissue-level research and does not show that any antioxidant prevents or treats Alzheimer's disease in people.
-
Alzheimer's disease (AD) is the most common cause of dementia in the elderly, and the fourth leading cause of death in the United States.
Why it matters
This review discusses chemokines and chemokine receptors in the central nervous system and their possible involvement in the inflammatory phenomena of Alzheimer's disease. It is a mechanistic overview and reports no treatment or prevention result.
-
Recent studies have shown that deficient functioning of glutamate transporters (GTs) in Alzheimer disease (AD) might lead to neurodegeneration.
Why it matters
In Alzheimer's frontal cortex, EAAT2 immunoreactivity and glutamate transporter activity were decreased while EAAT1 and EAAT3 were unaffected and mRNA levels for all three were unchanged. This is a tissue study describing a change in the brain and does not test any treatment.
-
Alternate cleavage products of intact 140- to 150-kd APPs in platelets include nonamyloidogenic 120- to 130-kd and 110-kd isoforms.
Why it matters
This study examined whether the ratio of two amyloid precursor protein isoforms in platelets correlates with Alzheimer's disease or the apolipoprotein E4 allele. It is a small platelet-based comparison and does not establish a treatment, cure, or prevention.
-
Atrophy of the CC differentiates HE and ID from AD subjects and tracks the cognitive decline of this disease.
Why it matters
This cross-sectional MRI study found that people with Alzheimer's disease had smaller corpus callosum size than healthy elderly or incipient dementia subjects, while the cerebellum and pons did not differ between groups. It describes a structural brain difference that may help distinguish Alzheimer's disease, but it does not test a treatment, cure, or prevention.
-
The spatial relationship of apolipoprotein E (apoE)-like immunoreactivity (IR) to amyloid beta-peptide (A beta), astrocytes and microglial cells in the brain of Alzheimer's disease was studied by double immunolabelling.
Why it matters
This brain tissue study found that microglial cells, not astrocytes, appear to be the main source of apoE buildup in senile plaques. It is a descriptive finding about disease tissue and does not test any treatment, cure, or prevention.
-
We studied the usefulness of measuring volumes of the hippocampus, amygdala and frontal lobes with coronal magnetic resonance imaging (MRI) scans in the diagnosis of early Alzheimer's disease (AD).
Why it matters
This study measured hippocampus, amygdala and frontal lobe volumes on MRI to aid diagnosis of early Alzheimer's disease and correlated them with memory functions. It is a diagnostic imaging study and does not test any treatment, cure or prevention.
-
45/100
Neuropathological findings in three aged chimpanzees were compared with those in rhesus monkeys and individuals with Alzheimer disease.
Why it matters
In three aged chimpanzees, senile plaques and blood vessels were immunoreactive for amyloid-beta-protein and apolipoprotein E, similar to findings in human aging and Alzheimer's disease, but neurofibrillary tangles were absent. This small animal study supports the value of aged primates for studying amyloid processing and apoE, but it does not offer a treatment or prevention.
-
The apolipoprotein E gene (APOE) has three common alleles (epsilon 2, epsilon 3, and epsilon 4) that determine six genotypes in the general population.
Why it matters
In this case-control study, the APOE epsilon4 allele was significantly more frequent in late-onset Alzheimer disease patients than controls, and the median age at onset decreased as the number of epsilon4 alleles increased. This supports APOE epsilon4 as a risk factor for Alzheimer disease but does not offer a treatment or cure.
-
A 59-year-old man developed problems with reading and driving.
-
A genetic component in the etiology of Alzheimer disease (AD) has been supported by indirect evidence for several years, with autosomal dominant inheritance with age-dependent penetrance being suggested to explain the familial aggregation of affecteds.
Why it matters
This linkage study examined chromosome 21 in familial Alzheimer's disease but found inconsistent results across studies. Some early-onset families showed linkage while studies of mainly late-onset families failed to confirm it, suggesting the possibility of genetic heterogeneity.
-
Out of a sample of 178 patients with AD, aggression was present in 20%, wandering in 19%, binge-eating in 10%, hyperorality in 6%, urinary incontinence in 48%, and sexual disinhibition in 7%.
-
Eight antisera and one monoclonal antibody to synthetic peptides that corresponded to domains extending over the entire length of the beta-amyloid precursor protein (beta-APP), and an antiserum to the full-length 695-amino acid form of the beta-APP, were raised to probe the composition of the core and corona of senile plaques (SPs).
Why it matters
Using antibodies to defined epitopes, this study found that beta-amyloid precursor protein domains outside the A4 region were largely restricted to senile plaque coronas in Alzheimer samples. It is a descriptive tissue study and does not test any treatment, cure or prevention.
-
Involvement of the immune system in the pathogenesis of Alzheimer's disease was demonstrated in two ways: by the attachment of complement proteins to diseased tissue, and by the activation of cells associated with the immune system.
Why it matters
This early study found complement proteins and activated immune cells in Alzheimer's brain tissue, indicating immune system involvement. It is a descriptive tissue study and does not show that any immune-based treatment helps patients.
-
Why it matters
Describes the clinical and neuropsychological assessment of Alzheimer's disease used by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD).
-
The expert panel from Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia discussed the current situation of various topics related to the diagnostics, general management and treatment of Alzheimer's disease (AD) in these Central Eastern European (CEE) countries, representing around 88 million population.
Why it matters
An expert panel from seven Central Eastern European countries (Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia; around 88 million people) set out to review Alzheimer's prevalence, patient and caregiver associations, registries, and whether diagnostic biomarkers and treatments are available and reimbursed in the region. It recommends that neurologists, psychiatrists and general practitioners work together on early diagnosis. It also calls for routine screening, telemedicine and remote monitoring, research into AI-based and digital tools, and reimbursement of diagnostic tests and therapy. These are expert recommendations, not tested results: the record reports no patient data and no country-by-country findings.
-
Anti-amyloid monoclonal antibody therapies (AATs) are increasingly used for the treatment of early symptomatic Alzheimer disease.
Why it matters
This review describes practical difficulties in reading brain MRI scans for ARIA during anti-amyloid antibody treatment, such as subtle FLAIR signal changes, unclear microhemorrhage counts, and overlapping ARIA-E and ARIA-H features. It offers management-oriented recommendations for these ambiguous cases, but does not test or report any treatment, cure, or prevention effect.
-
= 0.032). In individuals with LOUE, elevated plasma p-tau217 was associated with both cognitive impairment and disrupted sleep microarchitecture, with the most pronounced cognitive deficits observed in individuals with medication refractory epilepsy.
Why it matters
In people with late-onset unexplained epilepsy, elevated plasma p-tau217 was associated with both cognitive impairment and disrupted sleep microarchitecture, with the worst deficits in those whose seizures were medication refractory. This supports p-tau217 as a biomarker in this group and points to sleep processes, but it is not a treatment or cure.
-
= 0.036), with lower scores in PCA and lvPPA (median 21 and 21, respectively) compared with CBS-AD (median 27).
Why it matters
Among patients with atypical Alzheimer disease phenotypes, 70 to 85 percent would not meet criteria for anti-amyloid treatment, mostly because of bedside cognitive score thresholds. The authors conclude that phenotype-sensitive staging and patient selection are needed for treatment in atypical AD.
-
The potential role of aluminum (Al) in the onset and progression of Alzheimer disease (AD) remains among the most enduring and divisive controversies in environmental neurotoxicology.
Why it matters
This review of reviews weighed evidence on aluminum and Alzheimer's published since 2000. Lab studies show aluminum can promote several Alzheimer-related processes such as oxidative stress, amyloid beta aggregation and tau phosphorylation, while population studies are less consistent, though some link long-term or drinking-water exposure to higher risk. The authors conclude aluminum is neither the main cause of Alzheimer's nor irrelevant, but possibly a contributing factor, especially in susceptible people.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Olfactory bulb lesions in Alzheimer's disease
- The discriminant ability of the Eating Assessment Tool-10 to detect dysphagia and aspiration according to the stage of Alzheimer's disease
- Impact of race/ethnicity and area deprivation index on Alzheimer’s disease and related disorders biomarkers in the POINTER Cohort
- Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts
- Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort
- Obesity and White Matter Neuroinflammation Related Edema in Alzheimer's Disease Dementia Biomarker Negative Cognitively Normal Individuals
- High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
- Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study
- Dampening of Microglial Activation With Nasal Foralumab Administration in Moderate Alzheimer’s Disease Dementia
- Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology